NEXT-GEN METABOLIC CARE
“SMARTER DOSES, BETTER ADHERENCE.”
FACTORY SOLUTIONS
Pharawin develops advanced therapeutics for diabetes, dyslipidemia, and obesity, employing incretin agonists, SGLT-2 inhibitors, and extended-release platforms to improve adherence and outcomes. Biomarker-driven endpoints and digital tools are integrated from early development onward
GLP-1 Platforms
SGLT-2 Inhibitors
XR Solid Doses
Supportive Supplements